➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Boehringer Ingelheim
Mallinckrodt
AstraZeneca

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,124,630

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,124,630
Title:.omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy B. (Nishinomiya, JP), Scott; William J. (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (North Haven, CT), Natero; Reina (Hamden, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Application Number:09/993,647
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,124,630
Patent Claims: 1. A method for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon in a human or animal in need thereof comprising administering an effective amount of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)ph- enyl)urea of the formula: ##STR00186## N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula: ##STR00187## or a pharmaceutically acceptable salt thereof.

2. A method for the treatment of myeloid leukemia in a human in need thereof comprising administering an effective amount of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)ph- enyl)urea of the formula: ##STR00188## N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula: ##STR00189## or a pharmaceutically acceptable salt thereof.

3. A method of claim 1 for the treatment of carcinoma of the lung in a human in need thereof.

4. A method of claim 1 for the treatment of carcinoma of the pancreas in a human in need thereof.

5. A method of claim 1 for the treatment of carcinoma of the thyroid in a human in need thereof.

6. A method of claim 1 for the treatment of carcinoma of the bladder in a human in need thereof.

7. A method of claim 1 for the treatment of carcinoma of the colon in a human in need thereof.

8. A method for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon in a human or animal in need thereof comprising administering an effective amount of a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula: ##STR00190##

9. A method for the treatment of myeloid leukemia in a human in need thereof comprising administering an effective amount of a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-- pyridyloxy)phenyl)urea of the formula: ##STR00191##

10. A method of claim 8 for the treatment of carcinoma of the lung in a human in need thereof.

11. A method of claim 8 for the treatment of carcinoma of the pancreas in a human in need thereof.

12. A method of claim 8 for the treatment of carcinoma of the thyroid in a human in need thereof.

13. A method of claim 8 for the treatment of carcinoma of the bladder in a human in need thereof.

14. A method of claim 8 for the treatment of carcinoma of the colon in a human in need thereof.

15. A method for the treatment of villous colon adenoma comprising administering an effective amount of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)ph- enyl)urea of the formula: ##STR00192## N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula: ##STR00193## or a pharmaceutically acceptable salt thereof.

16. A method for the treatment of villous colon adenoma comprising administering an effective amount of a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula: ##STR00194##

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Harvard Business School
Colorcon
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.